Press Releases Bristol-Myers Squibb Company Wiener Boerse

Equities

BMYS

US1101221083

End-of-day quote Wiener Boerse Other stock markets 06:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
37.76 ^EUR	+1.25%		+1.52%	-18.53%

Jul. 11	Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	MT
Jul. 10	Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day	Jul. 08	BU
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America	Jul. 01	AQ
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	Jun. 24	AQ
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	Jun. 21	BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	Jun. 21	BU
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	Jun. 20	BU
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	Jun. 18	BU
Bristol Myers Squibb Announces Dividend	Jun. 18	BU
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	Jun. 13	BU
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	Jun. 05	AQ
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	Jun. 04	BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 04	BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	Jun. 03	BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	Jun. 03	BU
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	Jun. 01	BU
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	May. 30	BU
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	May. 29	BU
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	May. 23	BU
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	May. 23	BU
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab	May. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST